XT
MLYS icon

XTX Topco’s Mineralys Therapeutics MLYS Stock Holding History

XTX Topco’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Sell
68,407
-5,271
-7% -$155K 0.03% 896
2025
Q4 		$2.67M Buy
73,678
+54,838
+291% +$2.2M 0.07% 395
2025
Q3 		$714K Buy
+18,840
New +$408K 0.04% 804
2025
Q2 		– Sell
-13,785
Closed -$219K – 2868
2025
Q1 		$219K Buy
+13,785
New +$159K 0.01% 1644
2024
Q2 		– Sell
-14,992
Closed -$194K – 2237
2024
Q1 		$194K Buy
+14,992
New +$185K 0.03% 1189
2023
Q4 		– Sell
-18,670
Closed -$178K – 1903
2023
Q3 		$178K Buy
+18,670
New +$243K 0.03% 1055

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

XTX Topco's MLYS Position: Q1 2026 in Review

XTX Topco reduced its Mineralys Therapeutics (MLYS) stake by 7.2% in Q1 2026, selling an estimated $155K and leaving 68,407 shares worth $1.85M. The position accounts for 0.03% of the portfolio, ranked #896.

XTX Topco first reported a position in MLYS in Q3 2023 and has held it in 6 quarters since. The position peaked at $2.67M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • XTX Topco held 68,407 shares of Mineralys Therapeutics worth $1.85M as of Q1 2026.
  • XTX Topco sold 5,271 Mineralys Therapeutics shares in Q1 2026, an estimated $155K.
  • Mineralys Therapeutics made up 0.03% of XTX Topco's portfolio in Q1 2026, its #896 holding.
  • XTX Topco first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • XTX Topco's Mineralys Therapeutics position peaked at $2.67M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.